APA (7th ed.) Citation

H, K., & Y, H. (2025). Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial". Clinical and molecular hepatology, 31(1), 308. https://doi.org/10.3350/cmh.2024.0726

Chicago Style (17th ed.) Citation

H, Kanzaki, and Hoshida Y. "Transcriptomic Signature in Advanced Hepatocellular Carcinoma Tissue to Predict Combination Immunotherapy Response: Editorial on "Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial"." Clinical and Molecular Hepatology 31, no. 1 (2025): 308. https://doi.org/10.3350/cmh.2024.0726.

MLA (9th ed.) Citation

H, Kanzaki, and Hoshida Y. "Transcriptomic Signature in Advanced Hepatocellular Carcinoma Tissue to Predict Combination Immunotherapy Response: Editorial on "Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial"." Clinical and Molecular Hepatology, vol. 31, no. 1, 2025, p. 308, https://doi.org/10.3350/cmh.2024.0726.